Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many biological targets are considered "undruggable" due to limitations in traditional drug discovery methods, particularly when exploring the vast chemical space of peptides. Existing approaches often struggle to efficiently identify and optimize peptide drug candidates that can effectively interact with these challenging targets.
Solution
Perpetual Medicines is developing a computational platform that integrates computational physics and AI to enhance peptide drug discovery. Their platform is designed to explore a broader range of peptide chemical space, identify novel drug candidates, and address previously undruggable targets. By combining advanced computational methods with synthetic chemistry, the platform aims to accelerate the discovery process and improve the quality of identified peptide drug candidates. The platform leverages predictive power to optimize peptide design and interaction with target proteins.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing peptide therapeutics for challenging biological targets.
Features
- Computational physics-based modeling of peptide-target interactions
- AI-driven exploration of peptide chemical space
- Identification of peptide drug candidates for previously undruggable targets
- Integrated computational design and synthesis platform
- Advanced synthetic chemistry for peptide generation and optimization